# US 2014/0194367 A1 · Agrocybe aegerita lectin aal-2, and encoding gene thereof, preparation method therefor and application thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194367 A1 - Document ID: US20140194367A1 - Status: Published application - Kind: A1 - Application number: 14/235,770 - Filed: 2011-10-24 - Published: 2014-07-10 - Earliest claimed: 2011-08-01 - Assignees: Wuhan Alpha-Omega Biology Technology Co., Ltd(Cn) - Inventors: Hui Sun; Guojun Yu; Yalin Yin; Jinlin Zhang; Shuai Jiang; Bianli Gu; Yijie Chen - Web page: https://patentgrep.com/patent/US20140194367A1 ## CPC - C07K 14/375: from Basidiomycetes - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - G01N 33/57525: of the liver or pancreas - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - G01N 2333/4724: Lectins - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The isolated Agrocybe aegerita lectin AAL-2 is able to inhibit the growth of tumor cells by inducing apoptosis. In the animal study, the Agrocybe aegerita lectin AAL-2 has been showed to be capable for tumor therapy. Furthermore, the AAL-2 preferentially binds to the carbohydrate or glycoproteins with its N-Acetylglucosamine, which can be used for diagnosing the N-Acetylglucosamine-associated diseases or detecting N-Acetylglucosamine-modified carbohydrates. ## Claims ### Claim 1 An Agrocybe aegerita lectin AAL-2, characterized by that the amino acid sequence is set forth in (a) or (b): (a) The amino acid sequence set forth in SEQ ID NO: 2; or (b) The derived sequences obtained by the substitution, deletion or/and insertion of one or multiple amino acid residues in the amino acid sequence set forth in SEQ ID NO: 2 that still have the functions of amino acid as set forth in SEQ ID NO: 2. ### Claim 2 (depends on 1) A method for preparing Agrocybe aegerita lectin AAL-2 of claim 1, which contains the following steps of: (1) extracting the total protein of Agrocybe aegerita and removing the denatured proteins; (2) after removing the denatured proteins, purifying the Agrocybe aegerita total protein by affinity chromatography and using the buffer solution to wash the affinity column until no other proteins outflowing; (3) using the buffer solution to elute the affinity column and collecting the proteins. ### Claim 3 (depends on 2) The method according to claim 2, which is characterized by that: wherein the affinity column is the N-Acetylglucosamine conjugated Sepharose 6B affinity column; the buffer described in step (2) is PBS buffer; the buffer described in step (3) contains 0.2 mol/L N-Acetylglucosamine. ### Claim 4 (depends on 1) An cDNA encoding Agrocybe aegerita lectin AAL-2 characterized by that the cDNA nucleotide sequence is the following (a) or (b): (a) The nucleotide sequence set forth in SEQ ID NO: 1; or (b) Nucleotide sequence variations obtained through the substitution, deletion or/and insertion of one or multiple bases in the nucleotide sequence set forth in SEQ ID NO:1, the proteins encoded by which still have the functions of the Agrocybe aegerita lectin AAL-2 as claimed in claim 1. ### Claim 5 (depends on 4) The cDNA according to claim 4, wherein said cDNA is inserted into an expression vector. ### Claim 6 (depends on 5) The cDNA according to claim 5, wherein said expression vector is transformed into a host cell. ### Claim 7 (depends on 1) A pharmaceutical composition for curing the tumour is comprised of effective dose on treatment of the Agrocybe aegerita lectin AAL-2 claimed in claim 1 and the pharmaceutically acceptable vector. ### Claim 8 (depends on 1, 4) A Use of the Agrocybe aegerita lectin AAL-2 of claim 1 or the cDNA of claim 4 in the preparation of antitumor drugs. ### Claim 9 (depends on 1, 4) A Use of the Agrocybe aegerita lectin AAL-2 of claim 1 or the cDNA of claim 4 in the manufacture of a reagent which can be used to detect the N-Acetylglucosamine relevant diseases. ### Claim 10 (depends on 9) The use according to claim 9, wherein the manufacture of a reagent which can be used to detect the N-Acetylglucosamine relevant carbohydrate structure.